Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
The conference aims to bring various stakeholders and experts in the field of healthcare and digital solutions for ensuring ‘universal access to affordable and quality healthcare’
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
Subscribe To Our Newsletter & Stay Updated